Related Experiment Video
Updated: Jun 26, 2025
06:00
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
A PARP1-TIMELESS alliance in cancer therapy
1Genome Stability and Tumourigenesis Group, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Molecular Cell
|May 17, 2024
Summary
Poly (ADP-ribose) polymerase 1 (PARP1) works with TIMELESS and TIPIN to safeguard the genome during DNA replication. This finding is crucial for understanding PARP inhibitor therapies.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- Transcription-replication conflicts pose a threat to genome stability.
- Poly (ADP-ribose) polymerase 1 (PARP1) is a key enzyme in DNA repair.
- PARP inhibitors are a vital class of cancer therapeutics.
Purpose of the Study:
- To investigate the role of PARP1 in resolving transcription-replication conflicts.
- To identify novel interacting partners of PARP1 in genome protection.
- To elucidate the implications of these interactions for PARP inhibitor efficacy.
Main Methods:
- Co-immunoprecipitation assays to identify protein interactions.
- Cell-based assays to assess genome stability.
- Analysis of DNA replication and transcription dynamics.
Main Results:
- PARP1 physically interacts with the replisome components TIMELESS and TIPIN.
- This complex protects the genome by preventing or resolving transcription-replication conflicts.
- Depletion of PARP1, TIMELESS, or TIPIN leads to increased genomic instability.
Conclusions:
- PARP1, TIMELESS, and TIPIN form a functional complex to maintain genome integrity.
- This mechanism is critical for cellular survival under replication stress.
- Understanding this pathway may refine clinical applications of PARP inhibitors in cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:23Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K